Journal
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Volume 1876, Issue 1, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.bbcan.2021.188581
Keywords
PCSK9; Cancer; Apoptosis; Metastasis; Anti-tumor immunity; Targeted therapy
Categories
Funding
- Ministry of Human Resource Development, India
- Indian Institute of Technology Kharagpur, India
Ask authors/readers for more resources
PCSK9 has emerged as a novel pharmacological target for hypercholesterolemia and associated cardiovascular diseases, and its aberrant expression in a broad spectrum of cancers suggests its potential as a valuable biomarker and therapeutic target in personalized cancer medicine.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel pharmacological target for hypercholesterolemia and associated cardiovascular diseases owing to its function to mediate the degradation of low-density lipoprotein receptor (LDLR). Findings over the past two decades have identified novel binding partners and cellular functions of PCSK9. Notably, PCSK9 is aberrantly expressed in a broad spectrum of cancers and apparently contributes to disease prognosis, indicating that PCSK9 could be a valuable cancer biomarker. Experimental studies demonstrate the contribution of PCSK9 in various aspects of cancer, including cell proliferation, apoptosis, invasion, metastasis, anti-tumor immunity and radioresistance, strengthening the idea that PCSK9 could be a promising therapeutic target. Here, we comprehensively review the involvement of PCSK9 in cancer, summarizing its aberrant expression, association with disease prognosis, biological functions and underlying mechanisms in various malignancies. Besides, we highlight the potential of PCSK9 as a future therapeutic target in personalized cancer medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available